Mark Dybul

Mark Dybul

Company: Enochian BioSciences

Job title: Chief Executive Officer

Seminars:

Eliminating HBV for Sterilizing Cure: Is it Possible? 9:30 am

• Can infected hepatocytes be eliminated? • Is it possible to prevent relapse? • Would adjuvant immunotherapy be beneficial?Read more

day: Day Two

Panel Discussion: Defining Clinical Endpoints & Exploring Surrogates for HBV Functional Cure 8:30 am

• Reflecting cccDNA activity and assessing durability of hepatitis B surface antigen seroclearance • Outlining parameters for acceptable and clinically meaningful hepatitis B surface antigen loss and opportunities to implement alternative surrogate endpoints • Future directions: looking towards a sterilizing cureRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.